VIDEO: Vuity meets primary endpoint goals for near visual acuity improvement
Click Here to Manage Email Alerts
MONTEREY, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Cathleen M. McCabe, MD, discusses trial data for Vuity in the correction of presbyopia.
The study results showed that Vuity (pilocarpine hydrochloride ophthalmic solution 1.25%, Allergan) met primary endpoint goals for 3-line best-corrected near visual acuity improvement without a loss of more than 5 letters in distance acuity.
“There was also a large percentage of patients who achieved 20/40 or better near visual acuity at the 30-day, 1-hour and 3-hour endpoints,” McCabe said.
Collapse
McCabe CM. GEMINI 1 & 2 pooled phase 3 studies safety and efficacy: AGN-190584 primary and key secondary endpoints. Presented at: Women in Ophthalmology Summer Symposium; Aug. 25-28, 2022; Monterey, California (hybrid meeting).
Read more about
Click Here to Manage Email Alerts